Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties

Hepatology

Volumn 53, Issue 6, 2011, Pages 1864-1873

  Fioravanti, Jessica ^a   González, Iranzu ^a   Medina Echeverz, José ^a   Larrea, Esther ^a   Ardaiz, Nuria ^a   González Aseguinolaza, Gloria ^a   Prieto, Jesús ^a   Berraondo, Pedro ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; HYBRID PROTEIN; RECOMBINANT ALPHA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD TOXICITY; CELL DEATH; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VIVO STUDY; LYMPHOCYTE; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD36; ANTIVIRAL AGENTS; APOLIPOPROTEIN A-I; APOPTOSIS; CELL LINE; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HALF-LIFE; HEPACIVIRUS; HEPATITIS C; IMMUNIZATION; INTERFERON-ALPHA; LIVER; LYMPHOCYTES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTOR CROSS-TALK; RECEPTOR, INTERFERON ALPHA-BETA; RECOMBINANT FUSION PROTEINS;

EID: 79957443836     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24306     Document Type: Article

References (21)

1. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957; 147: 258-267.
2. Kalie E, Jaitin DA, Abramovich R, Schreiber G. An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities. J Biol Chem 2007; 282: 11602-11611.
3. Thyrell L, Erickson S, Zhivotovsky B, Pokrovskaja K, Sangfelt O, Castro J, et al. Mechanisms of Interferon-alpha induced apoptosis in malignant cells. Oncogene 2002; 21: 1251-1262.
4. Le Bon A, Etchart N, Rossmann C, Ashton M, Hou S, Gewert D, et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 2003; 4: 1009-1015.
5. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-1313.
6. Barnes E, Webster G, Jacobs R, Dusheiko G. Long-term efficacy of treatment of chronic hepatitis C with alpha interferon or alpha interferon and ribavirin. J Hepatol 1999; 31( Suppl 1): 244-249.
7. Fiorani C, Tonelli S, Casolari B, Sacchi S. The role of interferon-alpha in the treatment of myeloproliferative disorders. Curr Pharm Des 1999; 5: 987-1013.
8. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237-S244.
9. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000; 68: 556-567.
10. Subramanian GM, Fiscella M, Lamouse-Smith A, Zeuzem S, McHutchison JG. Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol 2007; 25: 1411-1419.
11. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996; 271: 518-520.
12. Wang YS, Youngster S, Grace M, Bausch J, Bordens R, Wyss DF. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev 2002; 54: 547-570.
13. Connelly MA, Williams DL. Scavenger receptor BI: a scavenger receptor with a mission to transport high density lipoprotein lipids. Curr Opin Lipidol 2004; 15: 287-295.
14. Nanjee MN, Crouse JR, King JM, Hovorka R, Rees SE, Carson ER, et al. Effects of intravenous infusion of lipid-free apo A-I in humans. Arterioscler Thromb Vasc Biol 1996; 16: 1203-1214.
15. Tape C, Kisilevsky R. Apolipoprotein A-I and apolipoprotein SAA half-lives during acute inflammation and amyloidogenesis. Biochim Biophys Acta 1990; 1043: 295-300.
16. Kim SI, Shin D, Choi TH, Lee JC, Cheon GJ, Kim KY, et al. Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I. Mol Ther 2007; 15: 1145-1152.
17. Shiow LR, Rosen DB, Brdickova N, Xu Y, An J, Lanier LL, et al. CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 2006; 440: 540-544.
18. Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 2009; 458: 904-908.
19. Kaser A, Nagata S, Tilg H. Interferon alpha augments activation-induced T cell death by upregulation of Fas (CD95/APO-1) and Fas ligand expression. Cytokine 1999; 11: 736-743.
20. Dondi E, Roue G, Yuste VJ, Susin SA, Pellegrini S. A dual role of IFN-alpha in the balance between proliferation and death of human CD4+ T lymphocytes during primary response. J Immunol 2004; 173: 3740-3747.
21. Pepinsky RB, LePage DJ, Gill A, Chakraborty A, Vaidyanathan S, Green M, et al. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity. J Pharmacol Exp Ther 2001; 297: 1059-1066.